Fluoxetine-rapid dissolve - Autism Therapeutics

Drug Profile

Fluoxetine-rapid dissolve - Autism Therapeutics

Alternative Names: AT 001 - Autism Thereapeutics; AT001 - Autism Therapeutics; NPL-2008; ODT fluoxetine - Autism Therapeutics; Serelsa; Zydis™ ODT fluoxetine

Latest Information Update: 27 May 2015

Price : $50

At a glance

  • Originator Mount Sinai School of Medicine
  • Developer Autism Therapeutics; Neuropharm
  • Class Antidepressants; Eye disorder therapies; Propylamines; Small molecules
  • Mechanism of Action Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autistic disorder
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Autistic disorder
  • New Molecular Entity No

Highest Development Phases

  • Phase III Autistic disorder

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 27 May 2015 Phase III development for Autistic disorder (In Children, In adolescents) is ongoing in the USA
  • 21 Dec 2011 Autism Therapeutics acquires Neuropharm
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top